Cited by 63Alzheimer's disease research and treatmentsCellular transport and secretionDementia and Cognitive Impairment Research

Sorting nexin 12 interacts with BACE1 and regulates BACE1-mediated APP processing

Open access
Zhao, Yonghao, Wang, Yunshu, Yang, Jiaye, Wang, Xin, Zhao, Yingjun, Zhang, Xian, Zhang, Yun-wu·2012·Molecular Neurodegeneration

Abstract

Background: β-site APP cleaving enzyme 1 (BACE1) cleaves β-amyloid precursor protein (APP) to initiate the production of β-amyloid (Aβ), the prime culprit in Alzheimer’s disease (AD). Dysregulation of the intracellular trafficking of BACE1 may affect Aβ generation, contributing to AD pathology. In this study, we investigated whether BACE1 trafficking and BACE1-mediated APP processing/Aβ generation are affected by sorting nexin 12 (SNX12), a member of the sorting nexin (SNX) family that is involved in protein trafficking regulation. Results: Herein, we find that SNX12 is widely expressed in brain tissues and is mainly localized in the early endosomes. Overexpression of SNX12 does not affect the steady-state levels of APP, BACE1 or γ-secretase components, but dramatically reduces the levels of Aβ, soluble APPβ and APP β-carboxyl terminal fragments. Downregulation of SNX12 has the opposite effects. Modulation of SNX12 levels does not affect γ-secretase activity or in vitro β-secretase activity. Further studies reveal that SNX12 interacts with BACE1 and downregulation of SNX12 accelerates BACE1 endocytosis and decreases steady-state level of cell surface BACE1. Finally, we find that the SNX12 protein level is dramatically decreased in the brain of AD patients as compared to that of controls. Conclusion: This study demonstrates that SNX12 can regulate the endocytosis of BACE1 through their interaction, thereby affecting β-processing of APP for Aβ production. The reduced level of SNX12 in AD brains suggests that an alteration of SNX12 may contribute to AD pathology. Therefore, inhibition of BACE1-mediated β-processing of APP by regulating SNX12 might serve as an alternative strategy in developing an AD intervention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1750-1326-7-30

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SNX12 downregulation increases BACE1 endocytosis and reduces cell-surface BACE1, thereby modulating β-cleavage of APP and Aβ production.

    “SNX12 binds to BACE1, and downregulation of SNX12 increases BACE1 endocytosis and reduces steady-state levels of BACE1 at the cell surface, thereby modulating β-cleavage of APP and consequent Aβ production [46].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 30 · Cited by 63

Authors
Zhao, Y., Wang, Y., Yang, J., Wang, X., Zhao, Y., Zhang, X., & Zhang, Y.-W.
Affiliations
  • Xiamen University (CN)
  • Sanford Burnham Prebys Medical Discovery Institute (US)
Corresponding author
Zhang, Yun-wu
Venue
Molecular Neurodegeneration
Published
2012-06-18
Volume
7
Issue
1
Pages
30-30
ISSN
1750-1326 (ISSN-L)
OpenAlex
W2125236697
Cited by
63
References
30
Citations by year
2025: 2 · 2024: 13 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 7 · 2014: 8 · 2013: 2
FWCI
3.64
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Neurodegeneration (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Alzheimer's Association
  • National Natural Science Foundation of China (81000540, 30973150, 81161120496)
  • Natural Science Foundation of Fujian Province (2009J06022)
  • Fok Ying Tung Education Foundation
  • Program for New Century Excellent Talents in University
  • Fundamental Research Funds for the Central Universities
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
BACE1, APP processing, amyloid-beta, Alzheimer's disease, early endosomes, protein trafficking, gamma-secretase
MeSH terms
Alzheimer Disease, Animals, Cells, Cultured, Humans, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Amyloid beta-Protein Precursor, Mice, Amyloid Precursor Protein Secretases, Sorting Nexins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review